This point is noteworthy since a previous report with copanlisib demonstrated a complete clinical responses in an endometrial cancer patient harbroing PIK3CA mutations in combination with PTEN loss (Patnaik et al., 2016). The gene discussed is PTEN; the disease is endometrial cancer.